LIDDS Stock Overview
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden.
LIDDS AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr6.86|
|52 Week High||kr15.66|
|52 Week Low||kr5.70|
|1 Month Change||-2.00%|
|3 Month Change||-7.80%|
|1 Year Change||-54.14%|
|3 Year Change||-61.02%|
|5 Year Change||-40.61%|
|Change since IPO||-37.64%|
Recent News & Updates
Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
|LIDDS||SE Biotechs||SE Market|
Return vs Industry: LIDDS underperformed the Swedish Biotechs industry which returned -22.1% over the past year.
Return vs Market: LIDDS underperformed the Swedish Market which returned -22% over the past year.
|LIDDS Average Weekly Movement||9.2%|
|Biotechs Industry Average Movement||9.7%|
|Market Average Movement||7.3%|
|10% most volatile stocks in SE Market||12.7%|
|10% least volatile stocks in SE Market||4.6%|
Stable Share Price: LIDDS is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: LIDDS's weekly volatility (9%) has been stable over the past year.
About the Company
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations.
LIDDS AB (publ) Fundamentals Summary
|LIDDS fundamental statistics|
Is LIDDS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LIDDS income statement (TTM)|
|Cost of Revenue||kr26.70m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 25, 2022
|Earnings per share (EPS)||-1.04|
|Net Profit Margin||-1,033.54%|
How did LIDDS perform over the long term?See historical performance and comparison